The classification of cyclooxygenase inhibitors

P. E. Lipsky, S. B. Abramson, L. Crofford, R. N. Dubois, L. S. Simon, L. B A Van de Putte

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.

Original languageEnglish (US)
Pages (from-to)2298-2303
Number of pages6
JournalJournal of Rheumatology
Volume25
Issue number12
StatePublished - 1998
Externally publishedYes

Fingerprint

Cyclooxygenase Inhibitors
Cyclooxygenase 2 Inhibitors
Non-Steroidal Anti-Inflammatory Agents
Analgesics
Anti-Inflammatory Agents
Clinical Trials
Hemorrhage
Incidence

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Lipsky, P. E., Abramson, S. B., Crofford, L., Dubois, R. N., Simon, L. S., & Van de Putte, L. B. A. (1998). The classification of cyclooxygenase inhibitors. Journal of Rheumatology, 25(12), 2298-2303.

The classification of cyclooxygenase inhibitors. / Lipsky, P. E.; Abramson, S. B.; Crofford, L.; Dubois, R. N.; Simon, L. S.; Van de Putte, L. B A.

In: Journal of Rheumatology, Vol. 25, No. 12, 1998, p. 2298-2303.

Research output: Contribution to journalArticle

Lipsky, PE, Abramson, SB, Crofford, L, Dubois, RN, Simon, LS & Van de Putte, LBA 1998, 'The classification of cyclooxygenase inhibitors', Journal of Rheumatology, vol. 25, no. 12, pp. 2298-2303.
Lipsky PE, Abramson SB, Crofford L, Dubois RN, Simon LS, Van de Putte LBA. The classification of cyclooxygenase inhibitors. Journal of Rheumatology. 1998;25(12):2298-2303.
Lipsky, P. E. ; Abramson, S. B. ; Crofford, L. ; Dubois, R. N. ; Simon, L. S. ; Van de Putte, L. B A. / The classification of cyclooxygenase inhibitors. In: Journal of Rheumatology. 1998 ; Vol. 25, No. 12. pp. 2298-2303.
@article{9b37265392284ed8abdd721f4d2e8235,
title = "The classification of cyclooxygenase inhibitors",
abstract = "In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.",
author = "Lipsky, {P. E.} and Abramson, {S. B.} and L. Crofford and Dubois, {R. N.} and Simon, {L. S.} and {Van de Putte}, {L. B A}",
year = "1998",
language = "English (US)",
volume = "25",
pages = "2298--2303",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "12",

}

TY - JOUR

T1 - The classification of cyclooxygenase inhibitors

AU - Lipsky, P. E.

AU - Abramson, S. B.

AU - Crofford, L.

AU - Dubois, R. N.

AU - Simon, L. S.

AU - Van de Putte, L. B A

PY - 1998

Y1 - 1998

N2 - In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.

AB - In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0031742183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031742183&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 2298

EP - 2303

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 12

ER -